Guideline Recommendations for Chlamydia Retesting and Test of Cure

Test of Cure (TOC)

The CDC does not recommend routine test‑of‑cure for non‑pregnant patients treated with standard regimens (doxycycline or azithromycin). 1, 2
TOC should be performed only in the following situations:
- Pregnant women: test at ≥ 3 weeks after completing therapy, preferably with a nucleic‑acid amplification test (NAAT). 1, 3
- Questionable adherence to the prescribed regimen. 2
- Persistent symptoms after therapy completion. 2
- Suspected reinfection due to exposure to untreated partners. 2
Testing before 3 weeks after treatment can yield false‑negative results because organism counts are still low. 1
Performing a NAAT before 3 weeks may produce false‑positive results from residual non‑viable organisms. 1, 2

All women should be retested ≈ 3 months after completing treatment to detect reinfection. 4, 1, 5
Women should also be retested at any visit occurring within 3–12 months after treatment, irrespective of partner‑treatment status. 4, 1, 5
Repeat infections in women are associated with a higher risk of pelvic inflammatory disease (PID) and related complications compared with a first infection. 4, 1, 5

Some specialists advise a ≈ 3‑month retest for men, although the supporting evidence is limited. 4, 1, 3

The majority of post‑treatment positive tests represent reinfection due to untreated sexual partners or new infected partners. 1, 5, 2

Do not perform a NAAT within 3 weeks of treatment completion, as this can generate false‑positive results from dead organisms. 1, 2
Do not confuse rescreening (detecting reinfection) with test‑of‑cure (verifying eradication); they target different populations and serve distinct purposes. 4, 1
Do not order routine TOC for non‑pregnant patients on recommended regimens; doing so wastes resources and may cause unnecessary anxiety from false‑positive findings. 2

Pregnant women must undergo a test‑of‑cure at ≥ 3 weeks after therapy to reduce maternal and neonatal morbidity. 1, 3
This TOC requirement applies regardless of the antibiotic used (azithromycin, amoxicillin, or erythromycin). 1, 3
Clinical evidence shows that appropriate TOC in pregnancy lowers the risk of adverse maternal and neonatal outcomes. 6

The CDC recommends that a test of cure is not routinely required for patients treated with doxycycline or azithromycin, except in pregnant women, when adherence to therapy is uncertain, or when symptoms persist after treatment. 7
Pregnant women should undergo a test of cure 3 weeks after completing therapy, preferably using culture, regardless of the antibiotic regimen used. 8
When therapeutic compliance is questionable, a test of cure should be performed to confirm eradication. 9
If symptoms continue after the prescribed course, a test of cure is indicated to assess for persistent infection. 10
In cases of suspected reinfection due to possible exposure to untreated partners, a test of cure may be considered. 7
For patients treated with erythromycin (a pregnancy‑compatible regimen), a test of cure may be performed 3 weeks after therapy completion. 11

In non‑pregnant patients who receive standard doxycycline or azithromycin regimens and are asymptomatic and compliant, routine retesting is unnecessary. 12
Routine follow‑up testing is not required for asymptomatic individuals when treatment adherence is assured. 13

Testing earlier than 3 weeks after treatment is not validated and can produce false‑negative results due to low residual organism counts. 8
Testing before 3 weeks can also yield false‑positive NAAT results because dead organisms may still be excreted. 14
When a test of cure is indicated, it should be performed at least 21 days (3 weeks) after therapy completion. 15
For pregnant women, the optimal window is 3–4 weeks post‑therapy. 12

The CDC advises that all women treated for chlamydia be rescreened 3 months after therapy to identify reinfection. 7
Reinfection rates are high because sexual partners often remain untreated. 15
Repeat infections carry a greater risk of pelvic inflammatory disease and other complications compared with a first infection. 12
Women should be re‑tested whenever they present for care within 3–12 months, irrespective of partner treatment status. 14
For men, some experts suggest rescreening ≈3 months after treatment, although supporting evidence is limited. 12
Men with documented chlamydia have high reinfection rates within 6 months and should be retested 3–6 months after therapy. 10

Do not perform NAAT testing within 3 weeks of completing treatment; this is likely to generate false‑positive results from residual non‑viable organisms. 12
Do not confuse rescreening with test of cure—they serve different purposes, have distinct timing, and target different populations. 7
Do not routinely order a test of cure for non‑pregnant patients treated with recommended regimens, as it wastes resources and may cause unnecessary anxiety from false‑positive findings. 14
Do not neglect partner treatment; untreated partners are the primary source of post‑treatment reinfections. 15